NEW YORK, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company dedicated to pioneering better, gentler medicines for brain disorders with significant unmet need, today
NEW YORK, Oct. 15, 2026 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE:ATNM) ("Actinium" or the "Company"), a pioneer in the development of targeted radiotherapies, today announced the appointment
NEW YORK, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company dedicated to pioneering better, gentler medicines for brain disorders with significant unmet need, today
First-ever oral direct KCC2 activator, OV4071, advancing in an ongoing Phase 1 studyInitiated Phase 2 proof-of-concept and photosensitivity studies for OV329, a next-generation GABA-AT inhibitorA newly-formed portfolio
Kevin Norrett, a proven leader in advancing corporate strategy through value-creating transactions, will be appointed as Chief Business OfficerCharles Carter promoted to Chief Financial Officer, reflecting his strong
NEW YORK, June 04, 2026 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company dedicated to pioneering better, gentler medicines for brain disorders with significant unmet need, today
NEW YORK, June 03, 2026 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company dedicated to pioneering better, gentler medicines for brain disorders with significant unmet need, today
Dosed first participant with OV4071, the first-ever oral potassium-chloride cotransporter 2 (KCC2) direct activator, in May 2026 in a Phase 1 study with healthy volunteersOV329 showed favorable safety, tolerability,
NEW YORK, April 08, 2026 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company developing small molecule medicines for brain disorders with significant unmet need, today announced the
The 7 mg dose of OV329 demonstrated favorable safety and tolerability profile, reinforcing best-in-category potential for refractory epilepsies; Ovid advancing plans to initiate a Phase 2 trial in focal onset seizures
Proceeds expected to support expansion of next-generation GABA-aminotransferase inhibitor, OV329, into tuberous sclerosis complex and infantile spasmsFinancing led by Point72 with participation from additional investors
NEW YORK, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company developing small molecule medicines to treat brain disorders and symptoms caused by excess neural
OV350 showed a good safety profile, supporting the advancement of the Company's KCC2 portfolio, including the first oral direct activator, OV4071There were no treatment-related laboratory findings, no safety findings,
NEW YORK, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company developing small molecule medicines for brain disorders with significant unmet need, today announced the
Meg Alexander appointed Chief Executive Officer effective January 1, 2026; Dr. Jeremy M. Levin to transition to Executive Chair of the Board of DirectorsNext-generation GABA-aminotransferase (GABA-AT) inhibitor, OV329,
